

Back passage of haemorrhagic septicaemia (HS) vaccine seed C82 in cattle calf

Nurulaini Raimy^{1*}, Ho Hung Wui¹, Abdul Sukor Shaharudin¹, Rohayu Mohd. Nasir¹, Lily Rozita Md. Hakin¹, Norliza Wahab¹ and Rohaiza Yahaya¹

¹Veterinary Research Institute (VRI), Department of Veterinary Services, No. 59, Jalan Sultan Azlan Shah, 31400, Ipoh, Perak, Malaysia

Received 14 June 2023

Accepted 6 August 2023

Online 31 December 2023

Keywords:

Haemorrhagic septicaemia,
Pasteurella multocida, vaccine,
VRI

✉*Corresponding author:

Nurulaini Raimy
Veterinary Research Institute
(VRI), Department of Veterinary
Services, No. 59, Jalan Sultan
Azlan Shah, 31400, Ipoh, Perak,
Malaysia
Email: nurulaini@dvs.gov.my

Abstract

Haemorrhagic septicaemia (HS) is caused by *Pasteurella multocida* serotypes B: 2, a Gram-negative coccobacilli bacterium. It causes fatal septicaemia with high mortality in cattle and buffaloes. Disease control and prevention are by effective HS vaccination in animals. A study was conducted on one mixed breed cattle calf for back passage of haemorrhagic septicaemia (HS) seed strain C82. Prior to bacterial inoculation in the calf, Mouse Protection Test (MPT) was conducted to ensure the calf is free from any HS antibody. The calf was injected subcutaneously with 0.5 ml dilutions of 10^{-3} of the bacteria incubated overnight (approximately 10^6 CFU/ml). After ± 30 hours of inoculation, a post-mortem was conducted on the calf showing signs of HS. Heart blood and organ samples were collected and cultured on blood agar to determine bacteria purity. Blood and organ samples were also sent to the bacteriology laboratory in VRI for confirmatory tests. The death of the calf is confirmed by re-isolation of *Pasteurella multocida* Type B. Heart blood collected was processed, freeze-dried and kept as vaccine seed for further usage in vaccine production. Revival of vaccine seed is needed to ensure its pathogenicity and functionality for production purposes.

©2023 UMK Publisher. All rights reserved.

1. INTRODUCTION

Haemorrhagic septicaemia (HS) is an acute, highly fatal form of pasteurellosis caused by certain serotypes of *Pasteurella multocida*, a gram-negative coccobacillus bacterium. The Asian serotype B:2 and the African serotype E:2 (Carter and Heddleston system), corresponding to 6:B and 6:E (Namioka-Carter system), are mainly responsible for the disease (OIE, 2021). It is one of the World Organisation for Animal Health (OIE) listed animal diseases and is considered as the most economically important bacterial disease of water buffalo and cattle in tropical areas of Asia. It may cause highly fatal septicaemia (blood poisoning) with high morbidity and mortality and infects mostly cattle and buffaloes (Bain et al., 1982; Carter & De Alwis, 1989; De Alwis, 1992; Singh et al., 1996). A study by Habib et al. (2019) revealed that the mortality, morbidity and case fatality rates due to HS were greater in young calves than the adults both in buffaloes and cattle.

The geographical distribution of HS includes some areas of Asia, Africa, the Middle East and southern Europe. It has never been confirmed in Mexico, Central or South America (OIE, 2021). HS was first reported as early as the 1880s in Malaysia (FAO, 1991). In 2017, it caused a loss of almost RM1.8 million due to the death of 298 cattle and 56 buffaloes in Terengganu (Bernama, 2017; Harian Metro, 2017). Multiple HS outbreaks have been reported

in Malaysia from 2017 to 2020, particularly in Terengganu. Malaysia has a population of cattle and buffaloes of 659,317 heads and 100,242 heads in 2020 which contributed to RM 1,595 million to our country (DVS, 2021). The most common and easy practice against HS is through the vaccination of animals (Zamri-Saad, 2013; Zamri-Saad and Annas, 2016). Veterinary Research Institute (VRI) under the Department of Veterinary Services (DVS) has been producing HS vaccines since 1949 (Lancaster, 1949). VRI started producing HS broth vaccine in 1949, HS Alum Precipitated (HSAP) in 1960, and HS Double Adjuvant (HSDA) in 1967 (Mustaffa-Babjee, 1994). For the past 10 years, a total of 514,725 doses of inactivated HS vaccines comprising 318,550 double adjuvant and 196,178 alum were produced. These vaccines were provided at no cost for Department of Veterinary Services (DVS) disease control and prevention activities and sold at a minimum price for private practitioners. HSAP and HSDA vaccine production using the *Pasteurella multocida* Type B strain C82 which originated from a local disease outbreak as vaccine seed (Thomas, 1968). Therefore, reviving the *Pasteurella multocida* Type B seed strain C82 is crucial to maintain the viability and pathogenicity of the bacteria. In this study, one mixed breed, male cattle calf was used for back passage of *Pasteurella multocida* Type B vaccine seed strain C82. Prior to bacterial inoculation in the calf, Passive

Mouse Protection Test (PMPT) was conducted to ensure the calf is free from any HS antibody. HS vaccine seed strain C82 was inoculated in the host as recommended by Gowrakkal et al. (2014) and Dagleish et al. (2007).

2. MATERIALS AND METHODS

2.1 Experimental design

A study was conducted on one mixed breed, male cattle calf for back passage of *Pasteurella multocida* Type B (PMB) seed strain C82. Prior to bacterial inoculation in the calf, Passive Mouse Protection Test (PMPT) was conducted to ensure the calf is free from any HS antibody. Mice were used as recommended by Bain et al. (1982) and Chandrasekaran et al. (1994). HS vaccine seed strain C82 was inoculated in host as recommended by Gowrakkal et al. (2014) and Dagleish et al. (2007).

2.2. Ethical approval

All animal handling procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of VRI with the animal ethics reference number IACUC/VRI (04/2019). Access to veterinary care was available at all times and the well-being of the animals used was assessed regularly.

2.3. Selection of cattle calf

Blood samples in EDTA and plain tubes were collected from sixteen cattle calves on a local government farm in Terengganu. Blood in plain tubes was centrifuged at 3000 x g for 15 minutes and processed for sera collection. Sera samples were also sent for melioidosis, brucellosis, Johne's disease, infectious bovine rhinotracheitis (IBR), bovine viral diarrhoea (BVD), bacterial isolation, virus isolation and Complete Blood Count (CBC) evaluation. All the sera samples were subjected to PMPT for evaluating immunity against HS vaccine in vaccinated or unvaccinated animals as described by Bain et al. (1982). Calves that are free from HS antibodies were selected for back passage of HS seed strain C82. Calves are free from other bacterial diseases that may interfere with the study. Selected animals were quarantined in VRI prior to inoculation and health screening was conducted.

2.4. Preparation of *Pasteurella multocida* Type B (strain C82)

A local strain of *Pasteurella multocida* C82 Carters type B was used in this study. First, the lyophilised seed was cultured on blood agar (BA - Oxoid; Cambridge, United Kingdom) supplemented with 5% cattle blood. An enriched liquid medium named Haemorrhagic Septicaemia Broth (HSB) which consists of mixture A (1% bacteriological peptone, 1% beef extract, 0.5% sodium chloride and 0.5% sodium bicarbonate in wt/vol) and mixture B (0.2% glucose, 0.4% yeast and 0.2% casein hydrolysate in wt/vol) was also prepared. The colonies in BA were evaluated according to their morphology and

subjected to Gram staining to visualize the bipolar bacterial cells. Isolated colonies from BA were reconstituted into 200 mL of HSB and incubated at 37°C for 24 h.

2.5. Passive Mouse protection Test (PMPT)

PMPT was carried out according to Bain et al. (1982) and Chandrasekaran et al. (1994) for evaluation of protective effects in the vaccinated calves. The use of PMPT as an indicator of protective status against HS was also described by Reddy and Srinivasan (1998) and Tabatabaei et al. (2007). Briefly, a group of five Swiss albino mice aged 6-7 weeks were injected subcutaneously with 0.5 ml of neat calf's serum and challenged with 100-200 CFU of *Pasteurella multocida* Type B broth after 24 hours. An equal number of untreated mice were included as a control. These mice were obtained from the VRI Animal House and maintained in the experimental room according to the VRI Institutional Animal Care Usage Committee (IACUC). Mortalities were recorded and the experiment terminated after 7 days of observation. Throughout the study, all dead animals were subjected to post-mortem examination. The organ samples were cut, transferred into a sterile Petri dish (47 cm x 33 cm x 47 cm) and processed on the same day for bacterial isolation at Bacteriology Laboratory, VRI. The results are expressed as the percentage surviving out of 5 after a challenge with bacteria.

2.6. Passage of haemorrhagic septicaemia (HS) vaccine seed strain C82 in cattle calf

One cattle calf of 7-8 months old, clinically healthy which is free towards HS antibody based on PMPT conducted previously was selected for back passage of *Pasteurella multocida* Type B seed strain C82 to revive its pathogenicity. The calf was injected subcutaneously with 0.5 ml dilutions of 10⁻³ of the bacteria (HS seed strain C82) incubated overnight (approximately 106 CFU/ml). After 28 hours post inoculation the calf showed clinical signs of HS i.e. difficulty of breathing, nasal discharge and collapsed (unable to stand). Post-mortem was conducted on the calf at about 30 hours post-inoculation. Organ samples (lung, heart, kidney, liver and spleen) were aseptically collected, put on a sterile Petri dish (47 cm x 33 cm x 47 cm) and cultured at the Bacterial Vaccine laboratory for isolation of *Pasteurella multocida* and sent for histopathology examination. Blood was collected aseptically from the heart and processed in a laboratory into small aliquots for long-term storage. The carcass was incinerated accordingly.

3. RESULT AND DISCUSSION

In PMPT calf serum inoculated in mice was challenged with diluted *Pasteurella multocida* Type B strain C82 bacterial broth. Two sera from cattle calves showed no protective effect (sero-negative) against *Pasteurella multocida* Type B in mice inoculated while the

other fourteen cattle sera showed a 100% mouse survival rate and the control group showed 100% mortality. *Pasteurella multocida* Carter's Type B was isolated in abundance from the mice organ samples. PMPT is used to differentiate vaccinated and non-vaccinated ruminants or who have acquired natural immunity against HS.

In this study, only one cattle calf was used for the back passage of vaccine seed C82. The other calf was not included during the experimental infection of *Pasteurella multocida* Type B. Post-mortem examination of all vital organs including the lung, heart, kidney, liver and spleen appeared to be hyperaemic, congested and haemorrhagic. The gastrointestinal tract such as oesophagus, abomasum, duodenum, jejunum, ileum, caecum and rectum also showed similar findings. Straw-coloured blood tinge fluid was found in the thoracic region. Histopathological examinations of organ samples showed moderate to severe haemorrhage and congestion; necrosis and degeneration; and inflammatory cell infiltration in all organs. Also, the lung showed mild to moderate oedema lesions.

Profuse growth of *Pasteurella multocida* Carter's Type B was found in heart blood and organ samples (lung, heart, kidney, liver and spleen) which indicated the septicaemia stage in animals causing death. *Pasteurella multocida* was confirmed by standard biochemical test and multiplex PCR (mPCR) by bacteriology Section VRI. Heart blood collected aseptically was stored as lyophilised cultures for further use in a -20 °C freezer. The *Pasteurella multocida* Type B strain C82 seed has been used in VRI for the past 20 years for HSAP and HSDA vaccine production. One recorded work of *Pasteurella multocida* vaccine seed passage was in 1965 via intranasal route into five calves (Chong, 1965). Four calves died and one calf was re-passaged via a subcutaneous route with 1.0 ml bacterial broth after the initial inoculation failed.

Calf selection in this study was based on PMPT followed by back passage of the C82 vaccine seed in cattle calves. PMPT is a recommended tool to evaluate the protective effect of the HS vaccine in animals (Bain et al., 1982; Chandrasekaran et al., 1994). It is used to differentiate vaccinated and non-vaccinated ruminants or who have acquired natural immunity against HS. A study by Phaswana et al. (2017) demonstrated the use of mice passive protection test to evaluate the humoral response in goats vaccinated with the Sterne 34F2 live spore vaccine. Mouse protection test was also used in suckling mice for the quantification of protective anti-foot-and-mouth disease virus (FMDV) antibodies (Mulcahy et al., 1991).

In our study, only two out of the sixteen calves were not having antibodies against HS. Therefore, one out of the two calves was chosen for back passage of *Pasteurella multocida* Type B strain C82 seed. Seropositive calf against HS could be due to maternal or active vaccination which we were unable to differentiate via PMPT.

Calf infected with the *Pasteurella multocida* Type B strain C82 culture showed respiratory distress, frothing from the mouth, nasal discharge, and subsequently recumbency and death 28 hours post-inoculation. The main characteristic feature of HS disease is septicaemia in all forms (OIE, 2021). At post-mortem there was also sero-sanguinolent fluid in the thoracic, pericardial and abdominal cavities with congested lungs. Although the incubation period of HS varies from 3 to 5 days, sudden death without clinical signs may be observed in peracute cases (OIE, 2021). Calf mortality due to HS showed that the vaccine seed C82 is still potent and able to cause HS experimentally.

Previous studies by Gowrakkal et al. (2014) reported that the immune efficiency of vaccine strain decreased when it is passed repeatedly in laboratory conditions (in vitro) therefore, it is important to conduct back passage in a natural host for longer immunopotency of the seed. Vaccine seed that was back passaged in its natural host had better immune efficiency to the culture than laboratory stock culture and it is recommended to conduct annual back passage of the vaccine seed culture of *Pasteurella multocida* bacteria for better establishment of immune potent vaccines (Gowrakkal et al., 2014).

Heart blood collected from the calf was processed and kept in lyophilised forms in 1 ml aliquots. For each new batch of the vaccine, an aliquot was thawed and cultured on a BA agar plate. Each seed used for vaccine production purposes will be tested according to purity, safety and efficacy as recommended by OIE and ASEAN Standards. OIE recommended that seed cultures be maintained as semi solid nutrient agar stab cultures at room temperature, or as lyophilised cultures.

Current findings indicated that back passage is useful to maintain the pathogenicity as well as to make sure vaccines produced by VRI using the C82 strain are working well. Seed strains may lose their potential or decrease immunopotential due to repeated passaging in unnatural hosts and stressful laboratory conditions.

Currently, VRI uses *Pasteurella multocida* Type B strain C82 culture for the production of HS Alum Precipitated (HSAP) and HS Double Adjuvant (HSDA). To date, VRI is still producing around 60,000 doses of HS vaccines annually for the local ruminant industry, particularly DVS. In the future, we aim to improve vaccine formulation in terms of viscosity or better vaccine efficacy and delivery in livestock.

4. CONCLUSION

Pasteurella multocida Type B strain C82 culture was successfully revived for further usage in vaccine production.

ACKNOWLEDGEMENTS

The authors would like to thank the Director General of the Department of Veterinary Services Malaysia and the Director of Veterinary Research Institute (VRI), Ipoh for permission to publish the work and also all staff involved in this study.

REFERENCES

- Bain, R. V. S., De Alwis, M. C. L., Carter, G. R., Gupta, B. K. (1982). Haemorrhagic septicaemia. FAO Animal Production and Health Paper No. 33. FAO, Rome, Italy.
- Bernama, (2017). Haemorrhagic septicaemia: No new deaths in Terengganu since Monday <https://www.astroawani.com/berita-malaysia/haemorrhagic-septicaemia-no-new-deaths-in-terengganu-since-monday-148498> (accessed 12 Oct 2020).
- Carter, G. R., De Alwis, M. C. L. (1989). Haemorrhagic septicaemia. In: Pasteurella and Pasteurellosis, Adlam C. & Rutter J.M., eds. Academic Press, London, UK, 131-160.
- Chandrasekaran, S., Kennett, I., Yeap, P. C., Muniandy, N., Rani, B., Mukkur, T. K. S. (1994). Characterization of immune response and duration of protection in buffaloes immunised with Haemorrhagic Septicaemia vaccines. Veterinary Microbiology, 41(3), 213-219.
- Chong, S. K. (1965). Report on the Veterinary Research Institute Federation of Malaya for the Year 1965.
- Dagleish, M. P., Hodgson, J. C., Ataei, S., Finucane, A., Finlayson, J., Sales, J., Coote, J., Parton, R. (2007). Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B: 2 against experimental hemorrhagic septicemia in calves. Infection and Immunity, 75(12), 5837-5844.
- De Alwis MCL (1992). Haemorrhagic septicaemia- a general review. Br.Vet. J. 148, 99-112.
- DVS, 2021. Malaysia: Livestock Population, 2019-2020. https://www.dvs.gov.my/dvs/resources/user_1/2020/BP/Perangkaan/Perangkaan_Ternakan_2019_2020_4_Jan_2021_final_combine.pdf. Assessed on 17 Feb., 2022.
- FAO, 1991. Proceedings of 4th International Workshop on Haemorrhagic Septicemia, FAO-APHCA, Kaudy, Sri Lanka; February 1991, pub. no. 13.
- Gowrakkal, M., Chandrashekar, M., Bhajantri, S., Jaykumar, S., Chandakala GC, Mayanna, A., Byregowda, S.M., Renukaprasad, C. (2014). Asian Pac J Trop Biomed 2014; 4(Suppl 1), S263-S267
- Habib F, Jabbar A, Shahnawaz R, Memon A, Yousaf A, Bilal M, Jamil T, Khalil R and Sharif A (2019). Prevalence of hemorrhagic septicemia in cattle and buffaloes in Tandojam, Sindh, Pakistan. Online J. Anim. Feed Res., 9(5), 187-190.
- Harian Metro (2017). 245 ternakan mati akibat hawar berdarah. Artikel ini disiarkan pada : Selasa, 6 Jun 2017 @ 6:27 PM (accessed 11 Feb., 2022).
- Lancaster, W.E. (1949). Veterinary Department Report. Federation of Malaya.
- Mulcahy G, Pullen LA, Gale C, DiMarchi RD, Doel TR. Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines. Vaccine. (1991) Jan; 9(1),19-24. doi: 10.1016/0264-410x(91)90311-s. PMID: 1848960.
- Mustaffa-Babjee A. (1994). History, development and prospects of the Animal Industry and Veterinary Services in Malaysia. Department of Veterinary Services Malaysia Publication. ISBN 983-99673-1-2, 953
- Phaswana PH, Ndumego OC, Koehler SM, Beyer W, Crafford JE, van Heerden H. Use of the mice passive protection test to evaluate the humoral response in goats vaccinated with Sterne 34F2 live spore vaccine. Vet Res. 2017 Sep 7;48(1), 46.
- Reddy, G.S. & Srinivasan, V.A. (1998). Assessment of serological response to haemorrhagic septicaemia vaccine by PMPT. The Indian Journal of Animal Sciences, 68(3), 234-235.
- Singh V.P, Kumar A.A., Srivastava S.K. & Rathore B.S. (1996). Significance of HS in Asia: India. International Workshop on Diagnosis and Control of HS. Bali, Indonesia, 28-30 May. Indonesian Department of Agriculture, Indonesia.
- Tabatabaei, M., Jula, G., Jabbari, A.R. & Esmailzadeh, M. (2007). Vaccine efficacy in cattle against hemorrhagic septicemia with live attenuated aroA mutant of Pasteurella multocida B: 2 strain. Journal of Cell and Animal Biology, 1. 62-65.
- Thomas J, 1968. Studies on haemorrhagic septicaemia oil adjuvant vaccine. I. Methods of production of vaccine. Kajian Vet, 1: 152-158.
- World Organisation for Animal Health (OIE). (2021). OIE Terrestrial Manual 2021, chapter 3.4.10: Haemorrhagic septicaemia (Pasteurella multocida)
- Zamri-Saad M (2013). Haemorrhagic Septicaemia of cattle and buffaloes in Asia. Malaysia: Universiti Putra Malaysia Press, Malaysia.
- Zamri-Saad M and Annas S, 2016. Vaccination against hemorrhagic septicemia of bovines: A review. Pak Vet J, 36(1): 1-5.